SOCS1/JAB is a negative regulator of LPS-induced macrophage activation

Immunity

Volumn 17, Issue 5, 2002, Pages 583-591

  Kinjyo, Ichiko ^a   Hanada, Toshikatsu ^a   Inagaki Ohara, Kyoko ^a   Mori, Hiroyuki ^a   Aki, Daisuke ^a   Ohishi, Masanobu ^a   Yoshida, Hiroki ^c   Kubo, Masato ^b   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE SIGNALING 1 SUPPRESSOR; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRITE; PROTEIN; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSYNTHESIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; KNOCKOUT MOUSE; MACROPHAGE ACTIVATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SEPTIC SHOCK; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

EID: 0036850946     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(02)00446-6     Document Type: Article

References (51)

1. Akira S., Takeda K., Kaisho T. Toll-like receptor. critical proteins linking innate and acquired immunity Nat. Immunol. 2:2001;675-680.
2. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M.et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:1999;597-608.
3. Beeson P.B. Tolerance to bacterial pyrogens. I. Factors influencing its development. J. Exp. Med. 86:1947;29-38.
4. Berczi I. Neurohormonal host defense in endotoxin shock. Ann. NY Acad. Sci. 840:1998;787-802.
5. Berlato C., Cassatella M.A., Kinjyo I., Gatto L., Yoshimura A., Bazzonia F. J. Immunol. 168:2002;6404-6411.
6. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
7. Crespo A., Filla M.B., Russell S.W., Murphy W.J. Indirect induction of suppressor of cytokine signaling-1 in macrophages stimulated with bacterial lipopolysaccharide. partial role of autocrine/paracrine interferon-β Biochem. J. 349:2000;99-104.
8. Crespo A., Filla M., Murphy W. Low responsiveness to IFN-gamma, after pretreatment of mouse macrophages with lipopolysaccharides, develops via diverse regulatory pathways. Eur. J. Immunol. 32:2002;710-719.
9. Cross A., Asher L., Seguin M., Yuan L., Kelly N., Hammack C., Sadoff J., Gemski P. Jr. The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. J. Clin. Invest. 96:1995;676-686.
10. Dalpke A.H., Opper S., Zimmermann S., Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166:2001;7082-7089.
11. Danner R.L., Elin R.J., Hosseini J.M., Wesley R.A., Reilly J.M., Parillo J.E. Endotoxemia in human septic shock. Chest. 99:1991;169-175.
12. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C., Chen Z.J. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:2000;351-361.
13. De Sepulveda P., Ilangumaran S., Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275:2000;14005-14008.
14. Eden C.S., Shahin R., Briles D. Host resistance to mucosal gram-negative infection. Susceptibility of lipopolysaccharide nonresponder mice. J. Immunol. 140:1988;3180-3185.
15. Fujita T., Nolan G.P., Liou H.C., Scott M., Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7:1993;1354-1363.
16. Ganster R.W., Taylor B.S., Shao L., Geller D.A. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl. Acad. Sci. USA. 98:2001;8638-8643.
17. Goldring C.E., Reveneau S., Pinard D., Jeannin J.F. Hyporesponsiveness to lipopolysaccharide alters the composition of NF-kappaB binding to the regulatory regions of inducible nitric oxide synthase gene. Eur. J. Immunol. 28:1998;2960-2970.
18. Greisman S.E., Young E.J., Woodward W.E. Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. J. Exp. Med. 124:1966;983-1000.
19. Gustafson G.L., Rhodes M.J., Hegel T. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock. Prog. Clin. Biol. Res. 392:1995;567-579.
20. Hagberg L., Hull R., Hull S., McGhee J.R., Michalek S.M., Svanborg Eden C. Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect. Immun. 46:1984;839-844.
21. Henricson B.E., Benjamin W.R., Vogel S.N. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 58:1990;2429-2437.
22. Kamizono S., Hanada T., Yasukawa H., Minoguchi S., Kato R., Minoguchi M., Hattori K., Morita S., Kitamura T., Kato H.et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276:2001;12530-12538.
23. Kastenbauer S., Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect. Immun. 67:1999;1553-1559.
24. Kawai T., Adachi O., Ogawa T., Takeda K., Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 11:1999;115-122.
25. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., Hoshino K., Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167:2001;5887-5894.
26. Kawazoe Y., Naka T., Fujimoto M., Kohzaki H., Morita Y., Narazaki M., Okumura K., Saitoh H., Nakagawa R., Uchiyama Y.et al. SSI-1/SOCS-1 family proteins inhibit insulin signal transduction pathway through modulating IRS-1 phosphorylation. J. Exp. Med. 193:2001;263-269.
27. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A. Jr., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 110:2002;191-202.
28. Marine J.C., Topham D.J., McKay C., Wang D., Parganas E., Stravopodis D., Yoshimura A., Ihle J.N. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 98:1999;609-616.
29. Medzhitov R., Janeway C. Jr. Innate immunity. N. Engl. J. Med. 343:2000;338-344.
30. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., Janeway C.A. Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell. 2:1998;253-258.
31. Metcalf D., Mifsud S., Di Rago L., Nicola N.A., Hilton D.J., Alexander W.S. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl. Acad. Sci. USA. 99:2002;943-948.
32. Morita Y., Naka T., Kawazoe Y., Fujimoto M., Narazaki M., Nakagawa R., Fukuyama H., Nagata S., Kishimoto T. SSI/SOCS-1 suppresses TNF a-induced cell death by regulation of p38 MAP kinase signal in fibroblast. Proc. Natl. Acad. Sci. USA. 97:2000;5405-5410.
33. Naka T., Matsumoto T., Narazaki M., Fujimoto M., Morita Y., Ohsawa Y., Saito H., Nagasawa T., Uchiyama Y., Kishimoto T. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor) deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;15575-15582.
34. Naka T., Tsutsui H., Fujimoto M., Kawazoe Y., Kohzaki H., Morita Y., Nakagawa R., Narazaki M., Adachi K., Yoshimoto T.et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity. 14:2001;535-545.
35. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 398:1999;252-256.
36. Nomura F., Akashi S., Sakao Y., Sato S., Kawai T., Matsumoto M., Nakanishi K., Kimoto M., Miyake K., Takeda K., Akira S. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J. Immunol. 164:2000;3476-3479.
37. Ohmori Y., Hamilton T.A. Requirement for STAT1 in LPS-induced gene expression in macrophages. J. Leukoc. Biol. 69:2001;598-604.
38. Poltorak A., He X., Smirnova I., Liu M.Y., Huffel C.V., Du X., Birdwell D., Alejos E., Silva M., Galanos C.et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice. mutations in Tlr4 gene Science. 282:1998;2085-2088.
39. Salkowski C.A., Detore G., Franks A., Falk M.C., Vogel S.N. Pulmonary and hepatic gene expression following cecal ligation and puncture. monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration Infect. Immun. 66:1998;3569-3578.
40. Shahin R.D., Engberg I., Hagberg L., Svanborg Eden C. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J. Immunol. 138:1987;3475-3480.
41. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1999;1777-1782.
42. Starr R., Willson T.A., Viney E.M., Murray L.J.L., Rayner J.R., Jenkins B.J., Alexander W.S., Metcalf D., Nicola N.A., Hilton D.J. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA. 95:1998;14395-14399.
43. Stoiber D., Kovarik P., Cohney S., Johnston J.A., Steinlein P., Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J. Immunol. 163:1999;2640-2647.
44. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K.et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 408:2000;600-605.
45. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
46. Toshchakov V., Jones B.W., Perera P.-Y., Thomas K., Cody M.J., Zhang S., Williams B.R.G., Major J., Hamilton T.A., Fenton M.J., Vog S.N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3:2002;392-398.
47. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J.N., Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1999;1309-1320.
48. Yasukawa H., Sasaki A., Yoshimura A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:2000;143-164.
49. Zhang J.G., Metcalf D., Rakar S., Asimakis M., Greenhalgh C.J., Willson T.A., Starr R., Nicholson S.E., Carter W., Alexander W.S.et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. USA. 98:2001;13261-13265.
50. Ziegler-Heitbrock H.W.L. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 45:1995;13-26.
51. Ziegler-Heitbrock H.W., Petersmann I., Frankenberger M. p50 (NF-kappa B1) is upregulated in LPS tolerant P388D1 murine macrophages. Immunobiology. 198:1997;73-80.